Comparative cytotoxicity of monocrotaline and its metabolites in cultured pulmonary artery endothelial cells

D. W. Taylor, Dennis W Wilson, M. W. Lamé, S. D. Dunston, A. D. Jones, H. J. Segall

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Metabolites of the pyrrolizidine alkaloid monocrotaline cause progressive development of pulmonary hypertension in rats. The putative reactive intermediate monocrotaline pyrrole (MCTP) has been shown to cause cytotoxicity, hypertrophy, decreased proliferation, and altered synthetic capability in cultured pulmonary endothelial cells. We compared effects of monocrotaline (MCT) at 60 μg/ml (0.185 mM) with previously identified metabolites, MCTP 10 μg/ml (0.031 mM) and glutathione-conjugated dihydropyrrolizine (GSH-DHP) 60 μg/ml (0.135 mM), in cultured bovine pulmonary artery endothelial cells (BPAECs). To determine whether endothelial metabolism might contribute to the mechanism of this toxicity, we used markers of cytotoxicity (LDH release), synthetic activity (PGI2 synthesis), hypertrophy (planimetry), cell density (cell count/area), and Evans blue albumin (EBA) transudation as a marker for loss of fluid barrier integrity. We found changes in all endothelial markers with MCTP only. MCTP caused increased LDH release by 48 hr, augmented PGI2 synthesis by 96 hr, and resulted in hypertrophy and decreased cell density by 48 hr that persisted at least 21 days. There was increased EBA transudation at 24 hr posttreatment. We concluded that, based on markers of endothelial damage, BPAECs showed no apparent ability to metabolize MCT to a reactive intermediate nor to further metabolize GSH-DHP to a toxic species. We also concluded that MCTP can cause a direct effect on fluid barrier integrity of endothelial cell monolayers in the absence of inflammation.

Original languageEnglish (US)
Pages (from-to)196-204
Number of pages9
JournalToxicology and Applied Pharmacology
Volume143
Issue number1
DOIs
StatePublished - Mar 1997

Fingerprint

Monocrotaline
Endothelial cells
Cytotoxicity
Metabolites
Pulmonary Artery
Endothelial Cells
Hypertrophy
Evans Blue
Cell Count
Epoprostenol
Albumins
Pyrrolizidine Alkaloids
Fluids
Poisons
Pulmonary Hypertension
Metabolism
Glutathione
Toxicity
Rats
Monolayers

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Comparative cytotoxicity of monocrotaline and its metabolites in cultured pulmonary artery endothelial cells. / Taylor, D. W.; Wilson, Dennis W; Lamé, M. W.; Dunston, S. D.; Jones, A. D.; Segall, H. J.

In: Toxicology and Applied Pharmacology, Vol. 143, No. 1, 03.1997, p. 196-204.

Research output: Contribution to journalArticle

Taylor, D. W. ; Wilson, Dennis W ; Lamé, M. W. ; Dunston, S. D. ; Jones, A. D. ; Segall, H. J. / Comparative cytotoxicity of monocrotaline and its metabolites in cultured pulmonary artery endothelial cells. In: Toxicology and Applied Pharmacology. 1997 ; Vol. 143, No. 1. pp. 196-204.
@article{056fa30cb59b44eeb842bc387148df63,
title = "Comparative cytotoxicity of monocrotaline and its metabolites in cultured pulmonary artery endothelial cells",
abstract = "Metabolites of the pyrrolizidine alkaloid monocrotaline cause progressive development of pulmonary hypertension in rats. The putative reactive intermediate monocrotaline pyrrole (MCTP) has been shown to cause cytotoxicity, hypertrophy, decreased proliferation, and altered synthetic capability in cultured pulmonary endothelial cells. We compared effects of monocrotaline (MCT) at 60 μg/ml (0.185 mM) with previously identified metabolites, MCTP 10 μg/ml (0.031 mM) and glutathione-conjugated dihydropyrrolizine (GSH-DHP) 60 μg/ml (0.135 mM), in cultured bovine pulmonary artery endothelial cells (BPAECs). To determine whether endothelial metabolism might contribute to the mechanism of this toxicity, we used markers of cytotoxicity (LDH release), synthetic activity (PGI2 synthesis), hypertrophy (planimetry), cell density (cell count/area), and Evans blue albumin (EBA) transudation as a marker for loss of fluid barrier integrity. We found changes in all endothelial markers with MCTP only. MCTP caused increased LDH release by 48 hr, augmented PGI2 synthesis by 96 hr, and resulted in hypertrophy and decreased cell density by 48 hr that persisted at least 21 days. There was increased EBA transudation at 24 hr posttreatment. We concluded that, based on markers of endothelial damage, BPAECs showed no apparent ability to metabolize MCT to a reactive intermediate nor to further metabolize GSH-DHP to a toxic species. We also concluded that MCTP can cause a direct effect on fluid barrier integrity of endothelial cell monolayers in the absence of inflammation.",
author = "Taylor, {D. W.} and Wilson, {Dennis W} and Lam{\'e}, {M. W.} and Dunston, {S. D.} and Jones, {A. D.} and Segall, {H. J.}",
year = "1997",
month = "3",
doi = "10.1006/taap.1996.8083",
language = "English (US)",
volume = "143",
pages = "196--204",
journal = "Toxicology and Applied Pharmacology",
issn = "0041-008X",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Comparative cytotoxicity of monocrotaline and its metabolites in cultured pulmonary artery endothelial cells

AU - Taylor, D. W.

AU - Wilson, Dennis W

AU - Lamé, M. W.

AU - Dunston, S. D.

AU - Jones, A. D.

AU - Segall, H. J.

PY - 1997/3

Y1 - 1997/3

N2 - Metabolites of the pyrrolizidine alkaloid monocrotaline cause progressive development of pulmonary hypertension in rats. The putative reactive intermediate monocrotaline pyrrole (MCTP) has been shown to cause cytotoxicity, hypertrophy, decreased proliferation, and altered synthetic capability in cultured pulmonary endothelial cells. We compared effects of monocrotaline (MCT) at 60 μg/ml (0.185 mM) with previously identified metabolites, MCTP 10 μg/ml (0.031 mM) and glutathione-conjugated dihydropyrrolizine (GSH-DHP) 60 μg/ml (0.135 mM), in cultured bovine pulmonary artery endothelial cells (BPAECs). To determine whether endothelial metabolism might contribute to the mechanism of this toxicity, we used markers of cytotoxicity (LDH release), synthetic activity (PGI2 synthesis), hypertrophy (planimetry), cell density (cell count/area), and Evans blue albumin (EBA) transudation as a marker for loss of fluid barrier integrity. We found changes in all endothelial markers with MCTP only. MCTP caused increased LDH release by 48 hr, augmented PGI2 synthesis by 96 hr, and resulted in hypertrophy and decreased cell density by 48 hr that persisted at least 21 days. There was increased EBA transudation at 24 hr posttreatment. We concluded that, based on markers of endothelial damage, BPAECs showed no apparent ability to metabolize MCT to a reactive intermediate nor to further metabolize GSH-DHP to a toxic species. We also concluded that MCTP can cause a direct effect on fluid barrier integrity of endothelial cell monolayers in the absence of inflammation.

AB - Metabolites of the pyrrolizidine alkaloid monocrotaline cause progressive development of pulmonary hypertension in rats. The putative reactive intermediate monocrotaline pyrrole (MCTP) has been shown to cause cytotoxicity, hypertrophy, decreased proliferation, and altered synthetic capability in cultured pulmonary endothelial cells. We compared effects of monocrotaline (MCT) at 60 μg/ml (0.185 mM) with previously identified metabolites, MCTP 10 μg/ml (0.031 mM) and glutathione-conjugated dihydropyrrolizine (GSH-DHP) 60 μg/ml (0.135 mM), in cultured bovine pulmonary artery endothelial cells (BPAECs). To determine whether endothelial metabolism might contribute to the mechanism of this toxicity, we used markers of cytotoxicity (LDH release), synthetic activity (PGI2 synthesis), hypertrophy (planimetry), cell density (cell count/area), and Evans blue albumin (EBA) transudation as a marker for loss of fluid barrier integrity. We found changes in all endothelial markers with MCTP only. MCTP caused increased LDH release by 48 hr, augmented PGI2 synthesis by 96 hr, and resulted in hypertrophy and decreased cell density by 48 hr that persisted at least 21 days. There was increased EBA transudation at 24 hr posttreatment. We concluded that, based on markers of endothelial damage, BPAECs showed no apparent ability to metabolize MCT to a reactive intermediate nor to further metabolize GSH-DHP to a toxic species. We also concluded that MCTP can cause a direct effect on fluid barrier integrity of endothelial cell monolayers in the absence of inflammation.

UR - http://www.scopus.com/inward/record.url?scp=0031106034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031106034&partnerID=8YFLogxK

U2 - 10.1006/taap.1996.8083

DO - 10.1006/taap.1996.8083

M3 - Article

VL - 143

SP - 196

EP - 204

JO - Toxicology and Applied Pharmacology

JF - Toxicology and Applied Pharmacology

SN - 0041-008X

IS - 1

ER -